Gebasaxturev

DB17296InvestigationalGene Therapies

Gebasaxturev: Overview.

Mechanism: Pharmacologically active on Complement decay-accelerating factor and Intercellular adhesion molecule 1
Curator reviewed
Also known as: Coxsackievirus A21 · Enterovirus human enterovirus C serogroup coxsackievirus serotype A21 · Human coxsackievirus A21
Code names: CVA-21 · V-937

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gebasaxturev, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.